

Associate Partners



Organized by



# 4<sup>th</sup> Annual Review on Head & Neck Cancers

22<sup>nd</sup>, 23<sup>rd</sup>, 29<sup>th</sup> & 30<sup>th</sup> OCT., 2021

## Organizing Chairpersons

Dr. B. K. Smruti

Dr. Pankaj Chaturvedi

Dr. Kumar Prabhash

## Organizing Secretaries

Dr. Mandar Deshpande

Dr. Sewanti Limaye

Dr. Kaustav Talapatra

## Scientific Committee Chair

Dr. Vanita Noronha

For registration visit

<https://www.riverroute.in/arhnc2021>

Virtual Webinar Managed by

**riverroute**

Leaders in Streaming Modules

Associate Partners



Organized by



# 4<sup>th</sup> Annual Review on Head & Neck Cancers

22<sup>nd</sup>, 23<sup>rd</sup>, 29<sup>th</sup> & 30<sup>th</sup> OCT., 2021

## Scientific Committee Members

Dr. Vijay Patil  
Dr. Nandani Menon  
Dr. Ajay Kumar  
Dr. Sunil Chopade  
Dr. Rohit Pai  
Dr. Akhil Kapoor  
Dr. Neha Mittal  
Dr. Abhishek Mahajan  
Dr. Poonam Joshi  
Dr. Monali Swain  
Dr. Shivkumar Thiagarajan  
Dr. Krishnakumar Thankappan  
Dr. Rakesh Pinninti  
Dr. Suhail Sayed

For registration visit

<https://www.riverroute.in/arhnc2021>

Virtual Webinar Managed by

**riverroute**  
Leaders in Streaming Modules

Associate Partners



Organized by



# 4<sup>th</sup> Annual Review on Head & Neck Cancers

## 22<sup>nd</sup>, 23<sup>rd</sup>, 29<sup>th</sup> & 30<sup>th</sup> OCT., 2021

### Welcome Address

On behalf of the organizing committee and Mumbai Oncology Association, we are pleased to invite you to the **"4th Annual Review on Head and Neck Cancers Conference"**. This will be a virtual conference and will be held through online webinar on **22-23-29-30 October 2021** (4 Hours a day).

The 4th Annual Review on Head and Neck Cancers Conference 2021 will provide practitioners an update in head and neck cancers with a comprehensive overview of the current standard of care practices as well as review of evolving and innovative treatment approaches. Management recommendations are rapidly evolving in this era of immune oncology and will receive particular attention, including a discussion of de-escalation and the current randomised trials evaluating de-escalation protocols.

The focus of this conference will be on latest in multidisciplinary approach to head and neck treatment, novel treatment breakthroughs and leading research publications and current best practices in supportive and survivorship care.

Distinguished faculty from Mumbai as well as from prominent National faculty will present a series of recent important publications followed by open panels which cover the management of malignancies in critical subsites within the head and neck such as the oral cavity, oropharynx, larynx, thyroid, and others. We will also cover important publications on rare subjects in head and neck cancers.

Open interaction between faculty and participants will be encouraged throughout the sessions. Participants are encouraged to pre-submit important problem statements needing Indian consensus.

We look forward to your active participation.

Regards

Organising Team

## For registration visit

<https://www.riverroute.in/arhnc2021>

Virtual Webinar Managed by

**riverroute**  
Leaders in Streaming Modules

Associate Partners



Organized by



# 4<sup>th</sup> Annual Review on Head & Neck Cancers

22<sup>nd</sup>, 23<sup>rd</sup>, 29<sup>th</sup> & 30<sup>th</sup> OCT., 2021

## Scientific Program

### Day 3, Friday, 29<sup>th</sup> October

5:55-6:00pm

Welcome and introduction

Academic Coordinators: **Vikas Kothavade**, Radiation Oncologist, Pune  
**Hitesh Singhavi**, Surgical Oncologist, Mumbai

6:00-6:30pm

This session is supported by BD/BARD

**Topic:** Choosing right VAD in cancer patients

**Speaker:** **Vineet Talwar**, Medical Oncologist, Delhi

### SESSION 6: KEY PUBLICATIONS IN RECURRENT/METASTATIC HEAD AND NECK CANCERS

**Chairpersons :** **Sumit Basu**, Radiation Oncologist, Mumbai (KDA)  
**Sandeep De**, Radiation Oncologist, Mumbai  
**Shirish Alurkar**, Medical Oncologist, Ahmedabad

6:30-6:40pm

**Reviewer:** **Pranav Chadha**, Radiation Oncologist, Mumbai

**Reirradiation using stereotactic body radiotherapy in the management of recurrent or second primary head and neck cancer: A meta-analysis and systematic review**

**Author:** **Jeongshim Lee**

**Citation:** Oral Oncol. 2020 Aug; 107:104757

**Endoscopic surgery compared with intensity-modulated radiotherapy in resectable locally recurrent nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial**

**Author:** **You-Ping Liu**

**Citation:** Lancet Oncol. 2021 Mar;22(3):381-390

For registration visit

<https://www.riveroute.in/arhnc2021>

Virtual Webinar Managed by

**riveroute**

Leaders in Streaming Modules



Associate Partners



Organized by



# 4<sup>th</sup> Annual Review on Head & Neck Cancers

22<sup>nd</sup>, 23<sup>rd</sup>, 29<sup>th</sup> & 30<sup>th</sup> OCT., 2021

## Scientific Program

### Day 3, Friday, 29<sup>th</sup> October

6:40-6:50pm **Reviewer: Udip Maheshwari, Medical Oncologist, Mumbai**

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial

**Author:** Joël Guigay

**Citation:** Lancet Oncol 2021; 22: 463–75

Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial

**Author:** Assuntina G Sacco

**Citation:** Lancet Oncol. 2021 Jun;22(6):883-892

6:50-7:00pm **Reviewer: Amol Dongre, Medical Oncologist, Nagpur**

Results of a randomized phase II study comparing pembrolizumab with methotrexate in elderly, frail or cisplatin-ineligible patients with relapsed or metastatic squamous cell carcinoma of the head and neck (RM-SCCHN)

**Author:** V. Gruenwald

**Citation:** j.annonc.2021.08.1322: 912P

Nivolumab and Ipilimumab in Metastatic Uveal Melanoma: Results From a Single-Arm Phase II Study

**Author:** Meredith S Pelster

**Citation:** J Clin Oncol. 2021 Feb 20; 39(6):599-607

For registration visit

<https://www.riverroute.in/arhnc2021>

Virtual Webinar Managed by

**riverroute**

Leaders in Streaming Modules

Associate Partners



Organized by



# 4<sup>th</sup> Annual Review on Head & Neck Cancers

22<sup>nd</sup>, 23<sup>rd</sup>, 29<sup>th</sup> & 30<sup>th</sup> OCT., 2021

## Scientific Program

### Day 3, Friday, 29<sup>th</sup> October

7:00-7:10pm **Reviewer: Santosh Kumar C, Medical Oncologist, Hyderabad**

Results of KEYNOTE-122: A phase III study of pembrolizumab (pembro) monotherapy vs chemotherapy (chemo) for platinum-pretreated, recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC)

**Author: A.T. Chan**

**Citation: j.annonc.2021.08.1268: 8580**

Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study

**Author: R L Ferris**

**Citation: Ann Oncol. 2020 Jul; 31(7):942-950.**

7:10-7:20pm **Reviewer: Waseem Abbas, Medical Oncologist, Delhi**

Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations

**Author: Alan L Ho**

**Citation: J ClinOncol. 2021 Jun 10;39(17):1856-1864.**

Dual blockade of EGFR and CDK4/6 delays head and neck squamous cell carcinoma progression by inducing metabolic rewiring

**Author: Sanjib Chaudhary**

**Citation: Cancer Lett. 2021 Jul 10;510:79-92.**

7:20-7:30pm **Reviewer: Nandini Menon, Medical Oncologist, Mumbai**

RMAC study: A randomized study evaluating the efficacy of metronomic adjuvant chemotherapy in patients with recurrent head and neck cancers post salvage surgery, not eligible for re-irradiation

**Author: N.S. Menon<sup>1</sup>**

**Citation: j.annonc.2021.08.1275: 865MO**

7:30-7:50pm Optimizing treatment for R/M SCC HN with immune checkpoint inhibitors

**Speaker: Vijay Patil, Medical Oncologist, Mumbai**

**Chairpersons :** Pankaj Shah, Medical Oncologist, Ahmedabad  
Asha Kapadia, Medical Oncologist, Mumbai

For registration visit

<https://www.riveroute.in/arhnc2021>

Virtual Webinar Managed by

**riveroute**

Leaders in Streaming Modules

Associate Partners



Organized by



# 4<sup>th</sup> Annual Review on Head & Neck Cancers

22<sup>nd</sup>, 23<sup>rd</sup>, 29<sup>th</sup> & 30<sup>th</sup> OCT., 2021

## Scientific Program

### Day 3, Friday, 29<sup>th</sup> October

7:50 -8:20pm Panel discussion on Key Publications in Recurrent/Metastatic Head and Neck Cancers

**Moderator:** Sewanti Limaye

**Panelists:** Kumar Prabhash, Medical Oncologist, Mumbai  
Peush Bajpai, Medical Oncologist, Delhi  
Prasad Eswaran, Medical Oncologist, Chennai  
Rejiv Rajindranath, Medical Oncologist, Chennai  
Ajeet Gandhi, Radiation Oncologist, Delhi  
Bhavesh Poladia, Medical Oncologist, Mumbai

### SESSION 7: KEY PUBLICATIONS IN SPECIAL POPULATION (RARE/HPV/ELDERLY)

**Chairpersons :** Devendra Chaukar, Surgical Oncologist, Mumbai  
Sadashivudu Gundeti, Medical Oncologist, Hyderabad

8:20-8:40pm Navigating treatment in our RM SCCN patients: Clinical trial to clinical practice

**Speaker:** Sameer Shrirangwar, Medical Oncologist, Nagpur

8:40-8:50pm **Reviewer:** Rakesh Reddy, Medical Oncologist, Bangalore

Prognostic significance of human papillomavirus status and treatment modality in hypopharyngeal cancer

**Author:** Nina Burbure

**Citation:** Head Neck. 2021 Oct; 43(10):3042-3052.

Survival Outcomes of De Novo vs Inverted Papilloma-Associated Sinonasal Squamous Cell Carcinoma A Systematic Review and Meta-analysis

**Author:** Jake J Lee

**Citation:** JAMA Otolaryngol Head Neck Surg. 2021 Apr 1; 147(4):350-359.

For registration visit

<https://www.riveroute.in/arhnc2021>

Virtual Webinar Managed by

**riveroute**<sup>®</sup>

▪ Leaders in Streaming Modules

Associate Partners



Organized by




# 4<sup>th</sup> Annual Review on Head & Neck Cancers

22<sup>nd</sup>, 23<sup>rd</sup>, 29<sup>th</sup> & 30<sup>th</sup> OCT., 2021

## Scientific Program


### Day 3, Friday, 29<sup>th</sup> October

8:50-9:00pm  **Reviewer: Gunjesh Kumar Singh, Medical Oncologist, Mumbai**

 Role of geriatric assessment in tailoring treatment of locally advanced head and neck cancer: The ELDERLY study

**Author: P. Bossi**

**Citation: j.annonc.2021.08.1274: 864MO**

 Safety and efficacy of concurrent chemoradiotherapy for head-and-neck cancers in older versus younger patients: Post hoc analysis of a randomized controlled trial

**Author: Gunjesh Kumar Singh**

**Citation: Cancer Res Stat Treat 2020; 3:482-8**

For registration visit

<https://www.riverroute.in/arhnc2021>

Virtual Webinar Managed by

**riverroute**

Leaders in Streaming Modules



Associate Partners



Organized by



# 4<sup>th</sup> Annual Review on Head & Neck Cancers

22<sup>nd</sup>, 23<sup>rd</sup>, 29<sup>th</sup> & 30<sup>th</sup> OCT., 2021

## Scientific Program

### Day 4, Saturday, 30<sup>th</sup> October

6:25-6:30pm

Welcome and introduction

Academic Coordinators: Nikhil Dharmadhikari, Surgical Oncologist  
Vaibhav Pareekh, Radiation Oncologist  
Hollis D'souza, Medical Oncologist

## SESSION 8: KEY PUBLICATIONS IN SUPPORTIVE CARE

Chairpersons : Vivek Kaushal, Radiation Oncologist, Rohtak  
SVSS Prasad, Medical Oncologist, Hyderabad

6:30-6:40pm

Reviewer: Charudatta Naik, MaxilloFacial Surgeon, Mumbai  
Pankaj Singhai, Physician, Bangalore

Assessment of the perceived stress and burden of family caregivers of the head-and-neck cancer patients at a tertiary care cancer center: A cross-sectional study

Author: S SathiyaPriya

Citation: J Cancer Res Ther. Jul-Sep 2021; 17(4):1039-1046.

Effect of Early Palliative Care on Quality of Life of Advanced Head and Neck Cancer Patients: A Phase III Trial

Author: Vijay MarutiPatil

Citation: J Natl Cancer Inst. 2021 Sep 4;113(9):1228-1237.

For registration visit

<https://www.riverroute.in/arhnc2021>

Virtual Webinar Managed by

**riverroute**

Leaders in Streaming Modules

Associate Partners



Organized by



# 4<sup>th</sup> Annual Review on Head & Neck Cancers

22<sup>nd</sup>, 23<sup>rd</sup>, 29<sup>th</sup> & 30<sup>th</sup> OCT., 2021

## Scientific Program

### Day 4, Saturday, 30<sup>th</sup> October

6:40-6:50pm **Reviewer: Bhooshan Zade, Radiation Oncologist, Pune**

Preventive use of gabapentin to decrease pain and systemic symptoms in patients with head and neck cancer undergoing chemoradiation

**Author: Derek K Smith**

**Citation: Head Neck.2020 Dec;42(12):3497-3505.**

Phase 3 Randomized Trial of Topical Steroid Versus Placebo for Prevention of Radiation Dermatitis in Patients With Head and Neck Cancer Receiving Chemoradiation

**Author: Tomoya Yokota**

**Citation: Int J RadiatOncolBiol Phys.2021 Nov 1;111(3):794-803.**

6:50-7:00pm **Reviewer: Vanita Noronha, Medical Oncologist, Mumbai**

Head and neck cancer patients under (chemo) radiotherapy undergoing nutritional intervention: Results from the prospective randomized HEADNUT-trial

**Author: AnastassiaLöser**

**Citation:j.radonc.2021.03.019**

Repurposing pantoprazole in advanced head and neck squamous cell carcinoma: A phase I/II randomized study

**Author: V. Noronha**

**Citation: j.annonc.2021.08.1321: 910P**

7:00-7:30pm **TBA**

For registration visit

<https://www.riverroute.in/arhnc2021>

Virtual Webinar Managed by

**riverroute**

Leaders in Streaming Modules

Associate Partners



Organized by



# 4<sup>th</sup> Annual Review on Head & Neck Cancers

22<sup>nd</sup>, 23<sup>rd</sup>, 29<sup>th</sup> & 30<sup>th</sup> OCT., 2021

## Scientific Program

Day 4, Saturday, 30<sup>th</sup> October

### SESSION 9: KEY PUBLICATIONS IN LA-H&SCC

**Chairpersons :** Shekhar Patil, Medical Oncologist, Bangalore  
A. K. Anand, Radiation Oncologist, Delhi

7:30-7:40pm **Reviewer:** Sarath Reddy, Radiation Oncologist, Solapur

ARTSCAN III: A Randomized Phase III Study Comparing Chemoradiotherapy With Cisplatin Versus Cetuximab in Patients With Locoregionally Advanced Head and Neck Squamous Cell Cancer

**Author:** Maria Gebre-Medhin.

**Citation:** J ClinOncol. 2021 Jan 1; 39(1):38-47.

Pattern of failure after curative (C-)RT in HNSCC: data from the phase III DAHANCA19 study

**Author:** Morten HorsholtKristensen

**Citation:** ESTRO 2021: PH-0048

7:40-7:45pm **Reviewer:** Aparna MP

Clinical profile and treatment outcomes of patients treated with induction chemotherapy for locally advanced carcinoma oral tongue: A retrospective analysis

**Author:** P. Govind RCC Trivandrum

**Citation:** j.annonc.2021.08.1312: 902P

7:45-7:50pm **Reviewer:** D Kukreja, Radiation Oncologist, Lucknow

Impact of induction chemotherapy (ICT) in borderline resectable or unresectable locally advanced oral squamous cell carcinoma (OSCC)

**Author:** D. Kukreja

**Citation:** j.annonc.2021.08.1325: 914P KGMS Lucknow

For registration visit

<https://www.riverroute.in/arhnc2021>

Virtual Webinar Managed by

**riverroute**

Leaders in Streaming Modules

Associate Partners



Organized by



# 4<sup>th</sup> Annual Review on Head & Neck Cancers

22<sup>nd</sup>, 23<sup>rd</sup>, 29<sup>th</sup> & 30<sup>th</sup> OCT., 2021

## Scientific Program

### Day 4, Saturday, 30<sup>th</sup> October

7:50-8:20pm  Panel discussion on Key Publications in Supportive Care

Moderator: Sarbani Laskar

Panelists: Rohit Malde, Radiation Oncologist, Mumbai  
Nidhi Patni, Radiation Oncologist, Jaipur  
Sudhir Nair, Surgical Oncologist, Mumbai  
U S Vishal Rao, Surgical Oncologist, Bangalore  
Chetan Deshmukh, Medical Oncologist, Mumbai  
Rajkumar Ramaswamy, Medical Oncologist, Madurai

For registration visit

<https://www.riverroute.in/arhnc2021>

Virtual Webinar Managed by

**riverroute**

Leaders in Streaming Modules



Associate Partners



Organized by



# 4<sup>th</sup> Annual Review on Head & Neck Cancers

22<sup>nd</sup>, 23<sup>rd</sup>, 29<sup>th</sup> & 30<sup>th</sup> OCT., 2021

## Scientific Program

Day 4, Saturday, 30<sup>th</sup> October

### SESSION 10: HEAD AND NECK CANCERS : INTERVENTIONS AND OTHERS

👤 Chairpersons : Anil D'cruz, Surgical Oncologist, Mumbai  
Moni Abraham, Surgical Oncologist, Cochin

8:20-8:30 pm 👤 Reviewer: Prakash N Pandit, Radiation Oncologist, Nashik

📖 Hypofractionated chemoradiation for head and cancer: Data from the PET NECK trial

Author: M Vreugdenhil

Citation: Oral Oncol. 2021 Feb;113:105112.

📖 Patterns of blood pressure changes in patients with head and neck cancer receiving radiotherapy or chemo-radiotherapy at a tertiary cancer centre

Author: Prakash N Pandit

Citation: Head Neck. 2021 Apr; 43(4):1280-1288.

8:30-8:40pm 👤 Reviewer: Shivakumar Thiagarajan, Surgical Oncologist, Mumbai

📖 Outcomes of combined use of topical and intravenous tranexamic acid on surgical field quality during functional endoscopic sinus surgery: Randomized controlled trial

Author: Hala Salah El-Din El-Ozairy

Citation: Head Neck. 2021 May; 43(5):1389-1397.

📖 Reliability of the 100 mL water swallow test in patients with head and neck cancer and healthy subjects Jorine A. Vermaire MSc1

Author: Jorine A Vermaire

Citation: Head Neck. 2021 Aug; 43(8):2468-2476.

8:40-8:50pm 👤 Reviewer: Agniva Basu, Surgical Oncologist, Kolkata

📖 Proposed modification to the Shamblin's classification of carotid body tumors: A single-center retrospective experience of 116 tumors

Author: GuangchaoGu

Citation: Eur J Surg Oncol. 2021 Aug; 47(8):1953-1960.

For registration visit

<https://www.riveroute.in/arhnc2021>

Virtual Webinar Managed by

**riveroute**

Leaders in Streaming Modules

Associate Partners



Organized by



# 4<sup>th</sup> Annual Review on Head & Neck Cancers

22<sup>nd</sup>, 23<sup>rd</sup>, 29<sup>th</sup> & 30<sup>th</sup> OCT., 2021

## Scientific Program

### Day 4, Saturday, 30<sup>th</sup> October

📖 Has the COVID 19 Pandemic caused a delay in treatment and disease progression of Head Neck Cancers? Analysis from Outpatient records of a single institution

Author: Rishik Raj Pathak

Citation: Journal of Head & Neck Physicians and Surgeons: Abstract 121

👥 Chairpersons : Shekhar Salkar, Surgical Oncologist, Goa  
P K Julka, Radiation Oncologist, Delhi

8:50-9:20pm 🗨️ Panel discussion on Head and Neck Cancers: Interventions and Others

Moderator: Vikram Kekatpure, Surgical Oncologist, Bangalore

Panelists: Prathamesh Pai, Surgical Oncologist, Mumbai  
Shamit Chopra, Surgical Oncologist, Mumbai  
Samarendra, Radiation Oncologist, Ahmedabad  
Dinesh Singh, Radiation Oncologist, Delhi  
Esha Jafa, Medical Oncologist, Lucknow  
Madhuchanda Kar, Medical Oncologist, Kolkata

For registration visit

<https://www.riveroute.in/arhnc2021>

Virtual Webinar Managed by

**riveroute**  
Leaders in Streaming Modules

# INDIAN EVIDENCE for INDIAN PATIENTS

In Locally Advanced Head & Neck Cancer

Significant Improvement in...  
**PFS & DFS is possible now**



**BIOMAb** EGFR<sup>®</sup>  
(Nimotuzumab Injection)

TARGET SUPERIOR OUTCOMES

**only**  
The <sup>Λ</sup> Anti-EGFR that has been proven to be  
efficacious in LASCCHN along with Cisplatin RT\*

Outcome of a large randomized trial done  
536 Head & Neck cancer patients

Reference: Patil VM, Noronha V, Joshi A, Agarwal J, Ghosh-Laskar S et al. A Randomized Phase 3 Trial Comparing Nimotuzumab Plus Cisplatin Chemoradiotherapy Versus Cisplatin Chemoradiotherapy Alone in Locally Advanced Head and Neck Cancer. Cancer 2019;0:1-14.

**Abridged Prescribing Information:** For the use only of an Oncologist or a Hospital or a Laboratory. **BIOMAb EGFR<sup>®</sup> (Nimotuzumab injection):** Refer to complete prescribing information leaflet before prescribing this product. Further information is available upon request. **Composition:** BIOMAb EGFR<sup>®</sup> Each 10mL vial contains: Nimotuzumab 50.0mg (Humanized anti EGFR monoclonal antibody), Sodium phosphate dibasic 18.0mg, Sodium phosphate monobasic 4.5mg, Sodium chloride 86.0mg, Polysorbate 80 2.0mg and Water for injection qs 10mL. **Indications:** Nimotuzumab is indicated for use in the treatment of advanced Squamous Cell Carcinoma of Head and Neck region with concurrent chemotherapy and/ or radiotherapy. **Dosage and Administration:** Nimotuzumab is administered as continuous intravenous (IV) infusions in weekly doses of 200mg for 6 weeks, in combination with a standard radiotherapy and/ or chemotherapy for head and neck cancers, 200mg of the antibody is diluted in 250mL of sodium chloride and infused over 60 minutes. During dilution with normal saline ensure that all precautions are taken to avoid accidental contamination. In case of any turbidity being seen in the solution it is due to accidental microbial contamination. In such case please discard the solution and prepare a fresh solution. **Contraindications:** None known. **Warnings and Precautions:** BIOMAb EGFR<sup>®</sup> should be used with caution in patients with known hypersensitivity to Nimotuzumab or to any of the known components of the formulation. Use in **Pregnancy and Lactation:** Human IgG1 is known to cross the placental barrier; but it is not known whether the antibody can cause fetal harm when administered to a pregnant woman. The antibody should only be given to a pregnant woman, or any woman not employing adequate contraception if the potential benefit outweighs the potential risk to the fetus. If the patient becomes pregnant while receiving this drug, she should be informed of the potential hazard to the fetus and/or the potential risk for loss of the pregnancy. Since human IgG1 is secreted in human milk, the potential for absorption and harm to the infant after ingestion is unknown. No recommendation is made on the potential benefit versus risk of administering Nimotuzumab to nursing mothers. **Undesirable Effects:** During clinical trials in patients with head and neck cancers, where Nimotuzumab was used concurrently with or without radiotherapy and/or chemotherapy, the commonly reported adverse events in the radiotherapy group were fever, chills, mucositis, pruritis, urticaria/rash, headache, hypertension and fluctuation in blood pressure. The reported adverse events in the chemo radiotherapy group were mucositis, asthenia, dizziness, haematuria (microscopic), vomiting and loose stools. Only rash and chills was rated by the investigator as certainly related to Nimotuzumab. Anaphylactic skin reaction was the only serious adverse event (SAE) reported due to Nimotuzumab, others were due to the underlying malignant disorder or as a result of treatment with concurrent chemotherapy or radiotherapy. In another clinical trial on advanced nasopharyngeal squamous carcinoma, the most frequently observed adverse reactions include low fever, hypotension, nausea, dizziness and skin rash. Adverse reactions observed in clinical trials when Nimotuzumab was used along with radiotherapy for the treatment of advanced epidermal derived tumors in head and neck cancers, were fever, tremors, nausea and vomiting, chills, hypotension, weakness, headache, anaemia and acral cyanosis. Most of the AEs reported during the trials when Nimotuzumab was combined with radiotherapy were associated with radiation; whereas nausea and fatigue were the most commonly reported non-radiation associated AEs. Irradiation toxicity was not exacerbated by the addition of Nimotuzumab to standard radiotherapy. **Presentation:** Available as single carton of 4 vials and each vial of 10mL (50.0 mg of Nimotuzumab).

**Manufactured By:** Biocon Limited, Special Economic Zone, Plot No. 2-4, Phase IV, Bommasandra-Jigani Link Road, Bommasandra Post, Bangalore – 560 099, India. **Marketed By:** Biocon Limited, 20<sup>th</sup> K.M., Hosur Road, Electronics City, Bangalore – 560100, India. Visit our website [www.biocon.com](http://www.biocon.com) or call toll free number: 1800 102 9465 or e-mail us at [drugsafety@biocon.com](mailto:drugsafety@biocon.com)



Some things in  
life should be  
**UNINTERRUPTED**

## Don't let lack of Venous Access disrupt the continuum of Chemotherapy

It may happen due to:



### Impact of Vesicant & Irritant Drugs

#### Phlebitis

70% patients receiving **vesicant/irritant** chemotherapy experience Phlebitis<sup>1</sup>

#### Extravasation

22% patients receiving **vesicant/irritant** chemotherapy experience extravasation<sup>2</sup>



Delivery  
Mechanism



### Repeated Venipuncture with PIV

Delivery of chemotherapy requires **multiple pricks** with PIV



Difficult Venous  
Access (DiVA)



### Difficult Venous Access (DiVA)

**1 out of every 3** adult patient has DiVA<sup>3</sup>

## BD Groshong® PICC is Designed to Provide Uninterrupted Central Access Leading to:



Lesser Vascular  
Complication<sup>4</sup>



Longer Dwell Time<sup>5</sup>



Reduced Venipuncture<sup>6</sup>

1. Mekuzad N et al. / IJPR (2012), 11 (4): 1065-1071.

2. International Journal Of Caring Sciences; 2012; May-August; Vol 5; Issue 2; 191-202

3. sou et al; BMC Nursing. (2017) 16:64.

4. REL GROUP (Rete Ematologica Lombarda - Lombardy Hematologic Network, Italy)

5. Part 6 NHS PICC Vascular Access Policy – Andrew Barton- January 2019 Version 3.

6. Lichner CA, Mangu PB, Wade JC, Camp-Sorrell D, Cope DG, El-Rayes BF, Gorman M, Ligibel J, Mansfield P, Levine M (2013) Central venous catheter care for the patient with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 31(10):1357–1370

Disclaimer: The information provided herein is not meant to be used, nor should it be used, to diagnose or treat any medical condition. All content, including text, graphics, images and information etc., contained in or available through this literature is for general information purposes only. For diagnosis or treatment of any medical condition, please consult your physician/doctor. BARD India Healthcare Private Limited or Becton Dickinson or their any of their subsidiaries, affiliates or their employees are not liable for any damages/claims to any persons in any manner whatsoever.

Bard India Healthcare Pvt. Ltd.  
501, Hubtown Solaris, N S Phadke Marg, Andheri East, Mumbai 400069  
Phone + 91 22 61361111  
E-Mail bard.india@crbard.com; bard.india@vsnl.net

bd.com

© 2020 BD, BD and BD Logo are trademarks of Becton, Dickinson and Company.





Associate Partners



Organized by



# 4<sup>th</sup> Annual Review on Head & Neck Cancers

22<sup>nd</sup>, 23<sup>rd</sup>, 29<sup>th</sup> & 30<sup>th</sup> OCT., 2021

WEBINAR MANAGED BY

**riverroute**<sup>®</sup>

▣ Leaders in Streaming Modules

**Yash Jain**

Conference Manager,

4<sup>th</sup> Annual Review on Head & Neck Cancers 2021

River Route Event, Mumbai

Mobile: +91 7718950974 | E-mail : rrcg.yash@gmail.com

---

Ground Floor, Ganesh Building, Adhyaru Industrial Estate,  
Lower Parel (W), Mumbai - 400 013

---

For registration visit

<https://www.riverroute.in/arhnc2021>

Virtual Webinar Managed by

**riverroute**<sup>®</sup>

▣ Leaders in Streaming Modules